

XXII

NIBIT 

MEETING

At the leading edge
of cancer biotherapy

23-25
OCTOBER 2025

Accademia Navale

L

I

V

O

R

N

O

12:00 | Arrival and Registration

13:30 | Welcome addresses

13:45 | INAUGURAL KEYNOTE LECTURE

Guido Kroemer (University of Paris, France)

Turning Danger into Cure:

The Immuno-Oncology Potential of the Danger Theory

**SESSION 1
MYELOID CELLS IN CANCER**

14:25 | **Jennifer Guerriero (Harvard Medical School – Boston, USA)**

Tbd

14:45 | Selected abstract

14:55 | Selected abstract

15:05 | Selected abstract

15:15 | General discussion

THURSDAY

SESSION 2
UNCOVERING THE MOLECULAR INTERACTIONS WITHIN
THE TUMOR MICROENVIRONMENT

15:40 | **Renato Ostuni** (Vita-Salute San Raffaele University - Milano, Italy)
Tbd

16:00 | Selected abstract

16:10 | Selected abstract

16:20 | Selected abstract

16:30 | **Gioacchino Natoli** (IEO, European Institute of Oncology -Milano, Italy)
Tbd

16:50 | General Discussion

17:15 | Poster Walk

18:15 | NIBIT General Assembly

19:30 | Welcome reception

OCTOBER 23

SESSION 3 B AND T CELLS IN CANCER

9:00 | **Wolf Fridman (University of Paris – France)**
B cells are pivotal players in response to immune check point inhibitors

09:20 | Selected abstract

09:30 | Selected abstract

09:40 | Selected abstract

09:50 | **Silvia Piconese (Sapienza University - Roma, Italy)**
BRCAing bad: Tregs in the tumor microenvironment

10:10 | General discussion

10:30 | Coffee break

SESSION 4 AI IN IMMUNE ONCOLOGY FROM RESEARCH TO CLINIC

11:00 | **Daniel Truhn (Aachen University, Germany)**
Healing with words - Large language models in oncology

11:20 | Selected abstract

11:30 | Selected abstract

11:40 | Selected abstract

11:50 | **Arsela Prelaj (Istituto Nazionale dei Tumori - Milano, Italy)**
AI for first Line immunotherapy prediction: from NSCLC to pancancer

12:10 | General discussion

13:00 | Lunch

FRIDAY

SESSION 5
EMPOWERING IMMUNE CELLS FOR ADOPTIVE CELL THERAPY

14:00	Concetta Quintarelli (Ospedale Pediatrico Bambino Gesù - Roma, Italy) <i>Tbd</i>
14:20	Selected abstract
14:30	Selected abstract
14:40	Ruggero De Maria (Catholic University - Roma, Italy) <i>Development of CAR T cell therapies for colorectal cancer</i>
15:00	Selected abstract
15:10	Chiara Bonini (Vita-Salute San Raffaele University - Milano, Italy) <i>Genome editing to overcome T cell exhaustion</i>
15:30	General discussion
16:00	Coffee break
16:30	Poster Walk
17:30	PEZCOLLER KEYNOTE LECTURE Marco Colonna (Washington University School of Medicine - St. Louis, USA) <i>Tbd</i>
18:20	Session ends
20:00	Social Dinner

OCTOBER 24

SESSION 6
IMMUNOTHERAPY. WHERE WE ARE AND WHERE WE ARE GOING

8:30	Tina Cascone (MD Anderson Cancer Center - Houston, USA) <i>tbd</i>
8:50	Selected abstract
9:00	Selected abstract
9:10	Sara Lonardi (IOV Istituto Oncologico Veneto - Padova, Italy) <i>Tbd</i>
9:30	Selected abstract
9:40	Paolo Ascierto (Istituto Nazionale Tumori "Fondazione G. Pascale" - Napoli, Italy) <i>tbd</i>
10:00	General discussion
10:30	Coffee break

SATURDAY

**SESSION 7
NEW TARGETS IN IMMUNE-ONCOLOGY**

10:45	Dario Neri (ETH Zürich – Switzerland) <i>Ligand-based delivery of cytokines and other payloads: from the bench to the clinic</i>
11:05	Selected abstract
11:15	Selected abstract
11:25	Selected abstract
11:35	Flavio Curnis (San Raffaele Scientific Institute - Milano, Italy) <i>Blockade of $\alpha\beta6$ and $\alpha\beta8$ integrins with a chromogranin A-derived peptide inhibits TGFβ activation in tumors and suppresses tumor growth</i>
11:55	General discussion
12:20	PARMIANI KEYNOTE LECTURE Laurence Zitvogel (University of Paris, France) <i>tbd</i>
13:00	NIBIT Awards Nominations
13:30	Adjourn

OCTOBER 25

VENUE

Accademia Navale
Livorno - IT

NIBIT BOARD

Paolo Ascierto, Napoli - IT
Vincenzo Bronte, Padova - IT
Giulia Casorati, Milano - IT
Mario Paolo Colombo, Milano - IT
Paola Nisticò, Roma - IT

Arsela Prelaj, Milano - IT
Maria Rescigno, Milano - IT
Antonio Sica, Milano - IT
Claudio Tripodo, Palermo - IT

REGISTRATION FEES

	Advance Registration <i>Closing at 23.59 on July 23</i>	Regular Registration
Participant over 35 – NIBIT member*	€ 220,00 VAT included	€ 250,00 VAT included
Participant under 35 – NIBIT member*	€ 120,00 VAT included	€ 150,00 VAT included
Post Doc – NIBIT member*	€ 120,00 VAT included	€ 150,00 VAT included
PhD Student – NIBIT member*	€ 120,00 VAT included	€ 150,00 VAT included
Resident – NIBIT member*	€ 120,00 VAT included	€ 150,00 VAT included
Non member (all categories)*	€ 320,00 VAT included	€ 350,00 VAT included
Undergraduate student	Free of charge	Free of charge

Social dinner € 50,00 VAT included

Open to all registered participants

* NIBIT member with settled payment of membership fee for 2024 and 2025

** Membership fee for 2025 is € 50; to become a member please fill in the form on www.nibit.org

To register, please access the link [here](#)

CALL FOR ABSTRACT

All participants are encouraged to submit an abstract in English.

The abstracts will be reviewed by the Scientific Committee and selected for oral or poster presentation.

When submitting the abstract, presenting authors must select one of the following topics

- Myeloid cells in cancer
- Uncovering the molecular interactions within the tumor microenvironment
- B and T cells in cancer
- AI in immune oncology from research to clinic
- Empowering immune cells for adoptive cell therapy
- Immunotherapy. Where we are and where we are going
- New targets in immune-oncology

The abstract should respect the following guidelines:

- The abstract must be submitted in English.
- Abstract title should be max 250 characters (spaces included) and should reflect the content of the abstract.
- Commercial names may not be used in the abstract title.
- No more than 10 authors can be listed. Only institutional affiliations, cities and countries
- should follow. One of the authors must be flagged as “Presenting author”.
- Abstracts should be organized under the headings:
 - Introduction
 - Methods
 - Results
 - Conclusions
- Tables and figures can be uploaded as a separate file (JPG, max 1 page)
- The online abstract submission procedure will not accept abstracts that exceed 500 words
- Abbreviations may be used if standard or if spelled out and defined at the first use.
- Compounds should be mentioned with the generic name, in lower case. Commercial names are admitted in the text, with an ®, and if in brackets following the generic name, i.e. “generic (Commercial ®)”

Abstract Selection Process

The Scientific Committee will make the selection of abstracts for the oral or poster presentation.

Please note that submitting an abstract does not constitute registration for the meeting.

To submit your abstract please access the link [here](#)

TRAVEL GRANTS

NIBIT will offer a limited number of Travel Grants.

The Grant will cover the travel expenses up to the amount of € 500. The reimbursement will be provided by bank transfer after the end of the meeting, upon receipt of flight and/or ground transportation tickets/invoices.

To be eligible you have to:

- Be the presenting author of a submitted abstract
- Be born after 1 November 1985

To apply, please upload a CV or a bio sketch, including your publications, when submitting the abstract.

Applications are subject to approval by the Scientific Committee